Where Does Axatilimab Fit in the Treatment Lineup?

The “off-the-shelf” CAR T-cell therapy CTD402 will be evaluated in a phase 1b/2 trial for patients with T-cell acute lymphoblastic leukemia and lymphoma.

Gwen Nichols, MD, discussed the impact of Medicaid reductions on patient care and how oncologists can advocate for accessible cancer treatment during these uncertain times.

The FDA cleared the investigational new drug application for LTZ-301, a first-in-class myeloid engager immunotherapy, with a phase 1 study set for mid-2025.

Gwen Nichols, MD, discussed the potential implications of recent funding cuts, how they are affecting academic and community oncologists, and what may be done to mitigate the damage.

A phase 2 study evaluated the use of ruxolitinib plus standard GVHD prophylaxis in patients with myelofibrosis undergoing transplant.

Axatilimab demonstrated consistent response and durability in chronic graft-versus-host disease, regardless of prior treatments, in a phase 1 AGAVE-201 trial analysis.